Contact
searchSearch
HMP Global
Login

Oncology

Featured

FDA Approval
FDA Expands Pirtobrutinib to First-Line Treatment of CLL/SLL Without 17p Deletion
10/02/2026
Stephanie Holland
Based on results from BRUIN CLL-313, the FDA approved pirtobrutinib for previously untreated CLL/SLL without a known 17p deletion, establishing a first-line treatment option supported by a significant progression-free survival benefit over...
Based on results from BRUIN CLL-313, the FDA approved pirtobrutinib for previously untreated CLL/SLL without a known 17p deletion, establishing a first-line treatment option supported by a significant progression-free survival benefit over...
Based on results from BRUIN...
10/02/2026
Oncology
Ajay Nooka, MD
Videos
Talquetamab-Based Combinations Significantly Improve Outcomes in Early Relapsed Multiple Myeloma
10/01/2026
Ajay Nooka, MD
Ajay Nooka, MD, discusses topline results from the phase 3 MonumenTAL-6 trial evaluating talquetamab-based combinations in early relapsed multiple myeloma, highlighting significant progression-free survival benefits and the potential for...
Ajay Nooka, MD, discusses topline results from the phase 3 MonumenTAL-6 trial evaluating talquetamab-based combinations in early relapsed multiple myeloma, highlighting significant progression-free survival benefits and the potential for...
Ajay Nooka, MD, discusses...
10/01/2026
Oncology
Sara Hurvitz, MD
Videos
Gedatolisib-Based Therapy Improves Progression-Free Survival in PIK3CA Wild-Type Advanced Breast Cancer
10/01/2026
Sara Hurvitz, MD
Sara Hurvitz, MD, discusses results from the phase 3 VIKTORIA-1 trial evaluating gedatolisib plus fulvestrant, with or without palbociclib, in patients with HR-positive, HER2-negative, PIK3CA wild-type advanced breast cancer following...
Sara Hurvitz, MD, discusses results from the phase 3 VIKTORIA-1 trial evaluating gedatolisib plus fulvestrant, with or without palbociclib, in patients with HR-positive, HER2-negative, PIK3CA wild-type advanced breast cancer following...
Sara Hurvitz, MD, discusses...
10/01/2026
Oncology
News
Cemiplimab Prolongs Survival Compared With Historical Systemic Treatment Options in Advanced Cutaneous Squamous Cell Carcinoma
10/01/2026
Emily Estrada
Results from the retrospective, real-world TOSCA trial demonstrated that cemiplimab improved overall and progression-free survival compared with historical systemic therapies in patients with locally advanced or metastatic cutaneous squamous...
Results from the retrospective, real-world TOSCA trial demonstrated that cemiplimab improved overall and progression-free survival compared with historical systemic therapies in patients with locally advanced or metastatic cutaneous squamous...
Results from the retrospective,...
10/01/2026
Oncology
News
Definitive Cemiplimab Shows Potential for Organ Preservation in Patients With Resectable Head and Neck Cutaneous Squamous Cell Carcinoma
10/01/2026
Emily Estrada
A retrospective trial found that definitive cemiplimab monotherapy provided durable disease control in selected patients with locally advanced, resectable head and neck cutaneous squamous cell carcinoma, supporting further evaluation of PD-1...
A retrospective trial found that definitive cemiplimab monotherapy provided durable disease control in selected patients with locally advanced, resectable head and neck cutaneous squamous cell carcinoma, supporting further evaluation of PD-1...
A retrospective trial found that...
10/01/2026
Oncology
John Mascarenhas, MD, Icahn School of Medicine at Mount Sinai
Videos
Selecting Second-Line Therapy After Hydroxyurea in Essential Thrombocythemia
10/01/2026
John Mascarenhas, MD
John Mascarenhas, MD, presents a case of hydroxyurea resistance and intolerance in essential thrombocythemia, highlighting the clinical decision to transition to ropeginterferon alfa-2b.
John Mascarenhas, MD, presents a case of hydroxyurea resistance and intolerance in essential thrombocythemia, highlighting the clinical decision to transition to ropeginterferon alfa-2b.
John Mascarenhas, MD, presents a...
10/01/2026
Oncology
News
Risvutatug Rezetecan More Than Doubles Response and Significantly Extends Survival in Patients With Relapsed Small Cell Lung Cancer
09/29/2026
Emily Estrada
Results from the phase 3 ARTEMIS-008 trial demonstrated that risvutatug rezetecan significantly improved overall and progression-free survival and response outcomes compared with topotecan in patients with small cell lung cancer who...
Results from the phase 3 ARTEMIS-008 trial demonstrated that risvutatug rezetecan significantly improved overall and progression-free survival and response outcomes compared with topotecan in patients with small cell lung cancer who...
Results from the phase 3...
09/29/2026
Oncology
News
Tambotatug Pelitecan Significantly Improves Survival Over Topotecan in Patients With Relapsed Small Cell Lung Cancer
09/27/2026
Emily Estrada
Results from the phase 3 TAISHAN-302 study demonstrated that tambotatug pelitecan significantly improved overall and progression-free survival compared with topotecan in patients with relapsed small cell lung cancer, supporting the...
Results from the phase 3 TAISHAN-302 study demonstrated that tambotatug pelitecan significantly improved overall and progression-free survival compared with topotecan in patients with relapsed small cell lung cancer, supporting the...
Results from the phase 3...
09/27/2026
Oncology
FDA Approval
FDA Approves Belzutifan Plus Lenvatinib Following Immunotherapy in Advanced Clear Cell Renal Cell Carcinoma
09/24/2026
Emily Estrada
Based on results from the LITESPARK-011 trial, the FDA has approved belzutifan plus lenvatinib following PD-1 or PD-L1 inhibitor therapy for patients with advanced clear cell renal cell carcinoma, providing a new combination treatment option...
Based on results from the LITESPARK-011 trial, the FDA has approved belzutifan plus lenvatinib following PD-1 or PD-L1 inhibitor therapy for patients with advanced clear cell renal cell carcinoma, providing a new combination treatment option...
Based on results from the...
09/24/2026
Oncology
News
First-Line Zipalertinib Plus Chemotherapy Significantly Improves Progression-Free Survival in EGFR Exon 20-Mutated Non-Small Cell Lung Cancer
09/24/2026
Emily Estrada
Results from the phase 3 REZILIENT 3 trial showed that adding zipalertinib to platinum-pemetrexed chemotherapy significantly improved progression-free survival and response in patients with previously untreated EGFR exon 20 insertion-mutated...
Results from the phase 3 REZILIENT 3 trial showed that adding zipalertinib to platinum-pemetrexed chemotherapy significantly improved progression-free survival and response in patients with previously untreated EGFR exon 20 insertion-mutated...
Results from the phase 3...
09/24/2026
Oncology
News
Amivantamab Plus Chemotherapy Extends Median OS in Final PAPILLON Analysis of EGFR Exon 20-Mutant Non-Small Cell Lung Cancer
09/24/2026
Emily Estrada
Final results from the phase 3 PAPILLON trial showed numerically prolonged overall survival with first-line amivantamab plus chemotherapy in patients with EGFR exon 20 insertion-mutated non-small cell lung cancer, despite substantial...
Final results from the phase 3 PAPILLON trial showed numerically prolonged overall survival with first-line amivantamab plus chemotherapy in patients with EGFR exon 20 insertion-mutated non-small cell lung cancer, despite substantial...
Final results from the phase 3...
09/24/2026
Oncology

Videos

Ajay Nooka, MD
Videos
Talquetamab-Based Combinations Significantly Improve Outcomes in Early Relapsed Multiple Myeloma
10/01/2026
Ajay Nooka, MD
Ajay Nooka, MD, discusses topline results from the phase 3 MonumenTAL-6 trial evaluating talquetamab-based combinations in early relapsed multiple myeloma, highlighting significant progression-free survival benefits and the potential for...
Ajay Nooka, MD, discusses topline results from the phase 3 MonumenTAL-6 trial evaluating talquetamab-based combinations in early relapsed multiple myeloma, highlighting significant progression-free survival benefits and the potential for...
Ajay Nooka, MD, discusses...
10/01/2026
Oncology
Sara Hurvitz, MD
Videos
Gedatolisib-Based Therapy Improves Progression-Free Survival in PIK3CA Wild-Type Advanced Breast Cancer
10/01/2026
Sara Hurvitz, MD
Sara Hurvitz, MD, discusses results from the phase 3 VIKTORIA-1 trial evaluating gedatolisib plus fulvestrant, with or without palbociclib, in patients with HR-positive, HER2-negative, PIK3CA wild-type advanced breast cancer following...
Sara Hurvitz, MD, discusses results from the phase 3 VIKTORIA-1 trial evaluating gedatolisib plus fulvestrant, with or without palbociclib, in patients with HR-positive, HER2-negative, PIK3CA wild-type advanced breast cancer following...
Sara Hurvitz, MD, discusses...
10/01/2026
Oncology
John Mascarenhas, MD, Icahn School of Medicine at Mount Sinai
Videos
Selecting Second-Line Therapy After Hydroxyurea in Essential Thrombocythemia
10/01/2026
John Mascarenhas, MD
John Mascarenhas, MD, presents a case of hydroxyurea resistance and intolerance in essential thrombocythemia, highlighting the clinical decision to transition to ropeginterferon alfa-2b.
John Mascarenhas, MD, presents a case of hydroxyurea resistance and intolerance in essential thrombocythemia, highlighting the clinical decision to transition to ropeginterferon alfa-2b.
John Mascarenhas, MD, presents a...
10/01/2026
Oncology
Naseema Gangat, MBBS
Videos
DISC-3405 Reduces Phlebotomy Requirements in Patients With Polycythemia Vera
09/24/2026
Naseema Gangat, MBBS
Naseema Gangat, MBBS, discusses results from the phase 2 RESTORE-PV trial evaluating DISC-3405 in patients with polycythemia vera, highlighting reductions in therapeutic phlebotomy requirements, improvements in patient-reported symptoms, and...
Naseema Gangat, MBBS, discusses results from the phase 2 RESTORE-PV trial evaluating DISC-3405 in patients with polycythemia vera, highlighting reductions in therapeutic phlebotomy requirements, improvements in patient-reported symptoms, and...
Naseema Gangat, MBBS, discusses...
09/24/2026
Oncology
Naseema Gangat, MBBS
Videos
Selcodebart Demonstrates Meaningful Anemia Responses in Patients With Myelofibrosis
09/23/2026
Naseema Gangat, MBBS
Naseema Gangat, MBBS, discusses results from the phase 2 RALLY-MF trial evaluating selcodebart for anemia in patients with myelofibrosis, highlighting durable hematologic responses across transfusion requirements, activity regardless of...
Naseema Gangat, MBBS, discusses results from the phase 2 RALLY-MF trial evaluating selcodebart for anemia in patients with myelofibrosis, highlighting durable hematologic responses across transfusion requirements, activity regardless of...
Naseema Gangat, MBBS, discusses...
09/23/2026
Oncology
Diana Osorio, MD, MPH, MD Anderson Cancer Center
Videos
Targeting BRAF V600E in Pediatric Cervicomedullary Ganglioglioma
09/18/2026
Diana Osorio, MD, MPH
Diana Osorio, MD, MPH, discusses the clinical significance of BRAF V600E in pediatric cervicomedullary ganglioglioma, highlighting the role of molecular profiling in guiding BRAF/MEK-targeted therapy and the practical considerations of...
Diana Osorio, MD, MPH, discusses the clinical significance of BRAF V600E in pediatric cervicomedullary ganglioglioma, highlighting the role of molecular profiling in guiding BRAF/MEK-targeted therapy and the practical considerations of...
Diana Osorio, MD, MPH, discusses...
09/18/2026
Oncology
Geoffrey Ku, MD
Videos
Zanidatamab-Based Regimens Redefine First-Line Treatment of HER2-Positive Gastroesophageal Adenocarcinoma
09/08/2026
Geoffrey Ku, MD
Geoffrey Ku, MD, discusses findings from the phase 3 HERIZON-GEA-01 trial evaluating first-line zanidatamab plus chemotherapy, with or without tislelizumab, in patients with HER2-positive gastroesophageal adenocarcinoma, highlighting improved...
Geoffrey Ku, MD, discusses findings from the phase 3 HERIZON-GEA-01 trial evaluating first-line zanidatamab plus chemotherapy, with or without tislelizumab, in patients with HER2-positive gastroesophageal adenocarcinoma, highlighting improved...
Geoffrey Ku, MD, discusses...
09/08/2026
Oncology
Viktor Grünwald, MD, PhD
Videos
Nivolumab Plus Ipilimumab Fails to Overcome Immunotherapy Resistance in Head and Neck Squamous Cell Carcinoma
09/02/2026
Viktor Grünwald, MD, PhD
Viktor Grünwald, MD, PhD, discusses results from the phase 2 OPTIM study evaluating nivolumab plus ipilimumab versus docetaxel after failure to respond to nivolumab in head and neck cancer, highlighting the need for novel strategies to...
Viktor Grünwald, MD, PhD, discusses results from the phase 2 OPTIM study evaluating nivolumab plus ipilimumab versus docetaxel after failure to respond to nivolumab in head and neck cancer, highlighting the need for novel strategies to...
Viktor Grünwald, MD, PhD,...
09/02/2026
Oncology
Allen Khudaverdyan, MD
Videos
Statin-Specific Effects May Influence Immunotherapy Outcomes in Patients With Head and Neck Squamous Cell Carcinoma
09/02/2026
Allen Khudaverdyan, MD
Allen Khudaverdyan, MD, discusses results from a large retrospective study evaluating concurrent statin use in patients with head and neck squamous cell carcinoma receiving immune checkpoint inhibitors, highlighting statin-specific survival...
Allen Khudaverdyan, MD, discusses results from a large retrospective study evaluating concurrent statin use in patients with head and neck squamous cell carcinoma receiving immune checkpoint inhibitors, highlighting statin-specific survival...
Allen Khudaverdyan, MD,...
09/02/2026
Oncology
Christopher Noel, MD, PhD
Videos
Perioperative Pembrolizumab May Not Be Cost-Effective in Advanced Head and Neck Cancer
09/02/2026
Christopher Noel, MD, PhD
Christopher Noel, MD, PhD, discusses a cost-effectiveness analysis of perioperative pembrolizumab in locally advanced head and neck cancer, highlighting how current drug pricing and treatment duration may limit cost-effectiveness despite the...
Christopher Noel, MD, PhD, discusses a cost-effectiveness analysis of perioperative pembrolizumab in locally advanced head and neck cancer, highlighting how current drug pricing and treatment duration may limit cost-effectiveness despite the...
Christopher Noel, MD, PhD,...
09/02/2026
Oncology

Insights From the ASCO Annual Meeting

News
First-in-Class Hepcidin Inhibitor DISC-0974 Demonstrates Activity in Myelofibrosis-Associated Anemia
07/09/2026
Stephanie Holland
Results from the ongoing, phase 2 RALLY-MF trial demonstrated that DISC-0974 produced meaningful hematologic responses and improved fatigue in patients with myelofibrosis-associated anemia, supporting hepcidin inhibition as a potential...
Results from the ongoing, phase 2 RALLY-MF trial demonstrated that DISC-0974 produced meaningful hematologic responses and improved fatigue in patients with myelofibrosis-associated anemia, supporting hepcidin inhibition as a potential...
Results from the ongoing, phase...
07/09/2026
Oncology
News
Imetelstat Maintains Overall Survival Advantage Over Best Available Therapy in JAK Inhibitor–Relapsed or Refractory Myelofibrosis
07/09/2026
Stephanie Holland
Updated results from a post hoc analysis demonstrated that imetelstat continued to improve overall survival compared with best available therapy in patients with JAK inhibitor relapsed or refractory myelofibrosis, despite substantial changes...
Updated results from a post hoc analysis demonstrated that imetelstat continued to improve overall survival compared with best available therapy in patients with JAK inhibitor relapsed or refractory myelofibrosis, despite substantial changes...
Updated results from a post hoc...
07/09/2026
Oncology
Ramaswamy Govindan, MD
Videos
Adjuvant Erlotinib Following Complete Resection of EGFR-Mutant Non-Small Cell Lung Cancer Improves Disease Free Survival But Not Overall Survival
06/29/2026
Ramaswamy Govindan, MD
Ramaswamy Govindan, MD, discusses results from the ALCHEMIST trial evaluating adjuvant erlotinib in resected EGFR-mutant non–small cell lung cancer and the potential for ongoing biomarker studies to identify patients most likely to benefit...
Ramaswamy Govindan, MD, discusses results from the ALCHEMIST trial evaluating adjuvant erlotinib in resected EGFR-mutant non–small cell lung cancer and the potential for ongoing biomarker studies to identify patients most likely to benefit...
Ramaswamy Govindan, MD,...
06/29/2026
Oncology
Erika Hamilton, MD
Videos
Tucatinib Demonstrates Consistent Benefit Across First-Line HER2-Positive Metastatic Breast Cancer Populations
06/26/2026
Erika Hamilton, MD
Erika Hamilton, MD, discusses updated results from the HER2CLIMB-05 trial showing that tucatinib added to trastuzumab and pertuzumab maintenance therapy improved outcomes across multiple clinically relevant subgroups of patients with...
Erika Hamilton, MD, discusses updated results from the HER2CLIMB-05 trial showing that tucatinib added to trastuzumab and pertuzumab maintenance therapy improved outcomes across multiple clinically relevant subgroups of patients with...
Erika Hamilton, MD, discusses...
06/26/2026
Oncology
Bjørn Henning Grønberg, MD, PhD
Videos
Concurrent Radiotherapy, Chemotherapy, and Durvalumab Does Not Improve Outcomes in Extensive-Stage Small Cell Lung Cancer
06/26/2026
Bjørn Henning Grønberg, MD, PhD
Bjørn Henning Grønberg, MD, PhD, discusses results from a phase 3 randomized trial evaluating the addition of concurrent thoracic radiotherapy to platinum/etoposide chemotherapy plus durvalumab in patients with extensive-stage small cell lung...
Bjørn Henning Grønberg, MD, PhD, discusses results from a phase 3 randomized trial evaluating the addition of concurrent thoracic radiotherapy to platinum/etoposide chemotherapy plus durvalumab in patients with extensive-stage small cell lung...
Bjørn Henning Grønberg, MD, PhD,...
06/26/2026
Oncology
Peter O’Donnell, MD
Videos
Health-Related Quality of Life Preserved with Neoadjuvant and Adjuvant Enfortumab Vedotin plus Pembrolizumab in Cisplatin-Ineligible Patients with Muscle-Invasive Bladder Cancer
06/26/2026
Peter O'Donnell, MD
Peter O’Donnell, MD, of the University of Chicago, discusses health-related quality-of-life (HRQoL) findings from the phase 3 KEYNOTE-905 study evaluating perioperative enfortumab vedotin plus pembrolizumab in patients with muscle-invasive...
Peter O’Donnell, MD, of the University of Chicago, discusses health-related quality-of-life (HRQoL) findings from the phase 3 KEYNOTE-905 study evaluating perioperative enfortumab vedotin plus pembrolizumab in patients with muscle-invasive...
Peter O’Donnell, MD, of the...
06/26/2026
Oncology
Sanjay Popat, PhD, FRCP
Videos
Pralsetinib Shows Improved Response in RET Fusion–Positive Advanced or Metastatic Non–Small Cell Lung Cancer
06/25/2026
Sanjay Popat, PhD, FRCP
Sanjay Popat, PhD, FRCP, medical oncologist at The Royal Marsden Hospital in London, England, discusses results from the phase 3 AcceleRET-Lung trial evaluating first-line pralsetinib versus standard-of-care histology-specific chemotherapy...
Sanjay Popat, PhD, FRCP, medical oncologist at The Royal Marsden Hospital in London, England, discusses results from the phase 3 AcceleRET-Lung trial evaluating first-line pralsetinib versus standard-of-care histology-specific chemotherapy...
Sanjay Popat, PhD, FRCP, medical...
06/25/2026
Oncology
Walter Weber, MD
Videos
Prepectoral Implant Placement Improves Long-Term Quality of Life After Breast Reconstruction
06/24/2026
Walter Weber, MD
Walter Weber, MD, discusses results from the phase 3 PREPEC trial showing that prepectoral implant-based breast reconstruction significantly improved long-term quality of life and physical well-being compared with subpectoral reconstruction...
Walter Weber, MD, discusses results from the phase 3 PREPEC trial showing that prepectoral implant-based breast reconstruction significantly improved long-term quality of life and physical well-being compared with subpectoral reconstruction...
Walter Weber, MD, discusses...
06/24/2026
Oncology
Timothy Cloughesy, MD
Videos
Vorasidenib Maintains Durable Clinical Benefit With Consistent Safety in IDH-Mutated Glioma
06/24/2026
Timothy Cloughesy, MD
Timothy Cloughesy, MD, discusses updated results from the INDIGO trial showing durable disease control, prolonged progression-free survival, and sustained safety with vorasidenib in patients with IDH-mutant grade 2 gliomas.
Timothy Cloughesy, MD, discusses updated results from the INDIGO trial showing durable disease control, prolonged progression-free survival, and sustained safety with vorasidenib in patients with IDH-mutant grade 2 gliomas.
Timothy Cloughesy, MD, discusses...
06/24/2026
Oncology
Peter Schmid, MD, PhD
Videos
Giredestrant Improves Outcomes Regardless of Menopausal Status in Early Breast Cancer
06/24/2026
Peter Schmid, MD, PhD
Peter Schmid, MD, PhD, discusses subgroup analysis results from the lidERA trial showing that giredestrant improved invasive disease-free and distant recurrence-free survival across premenopausal and postmenopausal patients with ER-positive,...
Peter Schmid, MD, PhD, discusses subgroup analysis results from the lidERA trial showing that giredestrant improved invasive disease-free and distant recurrence-free survival across premenopausal and postmenopausal patients with ER-positive,...
Peter Schmid, MD, PhD, discusses...
06/24/2026
Oncology

Insights From the ESMO Congress

Stephen Freedland, MD
Videos
Enzalutamide Plus Androgen Deprivation Therapy in Biochemically Recurrent Prostate Cancer
12/02/2025
Stephen J. Freedland, MD
Stephen Freedland, MD, discusses final overall survival results from the EMBARK study, which evaluated enzalutamide plus androgen deprivation therapy in patients with high-risk biochemical recurrence and negative conventional imaging.
Stephen Freedland, MD, discusses final overall survival results from the EMBARK study, which evaluated enzalutamide plus androgen deprivation therapy in patients with high-risk biochemical recurrence and negative conventional imaging.
Stephen Freedland, MD, discusses...
12/02/2025
Oncology
Brian Slomovitz, MD
Videos
Relacorilant Plus Nab-Paclitaxel in Recurrent Platinum-Resistant Ovarian Cancer
12/02/2025
Brian M. Slomovitz, MD, MS
Brian Slomovitz, MD, discusses updated findings from the ROSELLA trial evaluating relacorilant plus nab-paclitaxel in patients with recurrent platinum-resistant ovarian cancer.
Brian Slomovitz, MD, discusses updated findings from the ROSELLA trial evaluating relacorilant plus nab-paclitaxel in patients with recurrent platinum-resistant ovarian cancer.
Brian Slomovitz, MD, discusses...
12/02/2025
Oncology
Pasi Jänne, MD, PhD
Videos
Osimertinib Plus Chemotherapy Provides Broad Survival Benefit in EGFR-Mutant NSCLC
12/02/2025
Pasi Jänne, MD, PhD
Pasi Jänne, MD, PhD, discusses subgroup analysis results from the FLAURA2 trial evaluating osimertinib plus platinum-pemetrexed chemotherapy in patients with newly diagnosed EGFR-mutant non-small cell lung cancer.
Pasi Jänne, MD, PhD, discusses subgroup analysis results from the FLAURA2 trial evaluating osimertinib plus platinum-pemetrexed chemotherapy in patients with newly diagnosed EGFR-mutant non-small cell lung cancer.
Pasi Jänne, MD, PhD, discusses...
12/02/2025
Oncology
David Goldstein, MD
Videos
Regorafenib Plus Nivolumab Fails to Improve Outcomes in Gastric or Gastroesophageal Cancer
12/02/2025
David Goldstein, MD
David Goldstein, MD, discusses results from the INTEGRATE study which assessed regorafenib plus nivolumab in previously treated patients with gastric or gastroesophageal cancer.
David Goldstein, MD, discusses results from the INTEGRATE study which assessed regorafenib plus nivolumab in previously treated patients with gastric or gastroesophageal cancer.
David Goldstein, MD, discusses...
12/02/2025
Oncology
Sara Lonardi, MD
Videos
Dual Immunotherapy Delivers Durable Benefit in MSI-H/dMMR Metastatic Colorectal Cancer
11/13/2025
Sara Lonardi, MD
Sara Lonardi, MD, shares updated results from CheckMate 8HW comparing nivolumab plus ipilimumab with nivolumab alone or chemotherapy as first-line therapy for patients with MSI-H/dMMR metastatic colorectal cancer.
Sara Lonardi, MD, shares updated results from CheckMate 8HW comparing nivolumab plus ipilimumab with nivolumab alone or chemotherapy as first-line therapy for patients with MSI-H/dMMR metastatic colorectal cancer.
Sara Lonardi, MD, shares updated...
11/13/2025
Oncology
Sanjay Popat, MD, PhD
Videos
First-Line Zongertinib Demonstrates Promise in HER2-Mutated NSCLC
11/13/2025
Sanjay Popat, MD
Sanjay Popat, MD, PhD, discusses results from the phase 2 BEAMION-LUNG 1 trial evaluating zongertinib as a first-line treatment option for patients with advanced HER2-mutated non-small cell lung cancer.
Sanjay Popat, MD, PhD, discusses results from the phase 2 BEAMION-LUNG 1 trial evaluating zongertinib as a first-line treatment option for patients with advanced HER2-mutated non-small cell lung cancer.
Sanjay Popat, MD, PhD, discusses...
11/13/2025
Oncology
Janice Mehnert, MD
Videos
Pembrolizumab Lowers Distant Recurrence Risk in Resected Merkel Cell Carcinoma
11/10/2025
Janice Mehnert, MD
Janice Mehnert, MD, discusses results from the phase 3 STAMP trial evaluating pembrolizumab versus observation in patients with resected merkel cell carcinoma.
Janice Mehnert, MD, discusses results from the phase 3 STAMP trial evaluating pembrolizumab versus observation in patients with resected merkel cell carcinoma.
Janice Mehnert, MD, discusses...
11/10/2025
Oncology
Nima Nabavizadeh, MD
Videos
MCED Blood Test Detects Cancer Early With High Accuracy
11/10/2025
Nima Nabavizadeh, MD
Nima Nabavizadeh, MD, discusses results from the registrational phase 2 PATHFINDER-2 study evaluating an MCED multi-cancer early detection blood test in an intended-use population.
Nima Nabavizadeh, MD, discusses results from the registrational phase 2 PATHFINDER-2 study evaluating an MCED multi-cancer early detection blood test in an intended-use population.
Nima Nabavizadeh, MD, discusses...
11/10/2025
Oncology
Maria De Santis, MD
Videos
Addition of Durvalumab Strengthens Treatment for Patients With High-Risk Non–Muscle Invasive Bladder Cancer
11/10/2025
Maria De Santis, MD
Maria De Santis, MD, discusses results from the phase 3 POTOMAC trial evaluating the addition of durvalumab to bacillus Calmette-Guérin induction and maintenance therapy among patients with high-risk non-muscle invasive bladder cancer.
Maria De Santis, MD, discusses results from the phase 3 POTOMAC trial evaluating the addition of durvalumab to bacillus Calmette-Guérin induction and maintenance therapy among patients with high-risk non-muscle invasive bladder cancer.
Maria De Santis, MD, discusses...
11/10/2025
Oncology
Dean Fennell, MD, PhD
Videos
Intratumor Heterogeneity Predicts Niraparib Benefit in Relapsed Mesothelioma
11/10/2025
Dean Fennell, MD, PhD
Dean Fennell, MD, PhD, discusses results from the investigator-initiated phase 2 NERO trial evaluating niraparib plus active symptom control versus active symptom control alone in patients with relapsed mesothelioma.
Dean Fennell, MD, PhD, discusses results from the investigator-initiated phase 2 NERO trial evaluating niraparib plus active symptom control versus active symptom control alone in patients with relapsed mesothelioma.
Dean Fennell, MD, PhD, discusses...
11/10/2025
Oncology

Live Meetings

Recent News

FDA Approval
FDA Expands Pirtobrutinib to First-Line Treatment of CLL/SLL Without 17p Deletion
10/02/2026
Stephanie Holland
Based on results from BRUIN CLL-313, the FDA approved pirtobrutinib for previously untreated CLL/SLL without a known 17p deletion, establishing a first-line treatment option supported by a significant progression-free survival benefit over...
Based on results from BRUIN CLL-313, the FDA approved pirtobrutinib for previously untreated CLL/SLL without a known 17p deletion, establishing a first-line treatment option supported by a significant progression-free survival benefit over...
Based on results from BRUIN...
10/02/2026
Oncology
News
Risvutatug Rezetecan More Than Doubles Response and Significantly Extends Survival in Patients With Relapsed Small Cell Lung Cancer
09/29/2026
Emily Estrada
Results from the phase 3 ARTEMIS-008 trial demonstrated that risvutatug rezetecan significantly improved overall and progression-free survival and response outcomes compared with topotecan in patients with small cell lung cancer who...
Results from the phase 3 ARTEMIS-008 trial demonstrated that risvutatug rezetecan significantly improved overall and progression-free survival and response outcomes compared with topotecan in patients with small cell lung cancer who...
Results from the phase 3...
09/29/2026
Oncology
News
Tambotatug Pelitecan Significantly Improves Survival Over Topotecan in Patients With Relapsed Small Cell Lung Cancer
09/27/2026
Emily Estrada
Results from the phase 3 TAISHAN-302 study demonstrated that tambotatug pelitecan significantly improved overall and progression-free survival compared with topotecan in patients with relapsed small cell lung cancer, supporting the...
Results from the phase 3 TAISHAN-302 study demonstrated that tambotatug pelitecan significantly improved overall and progression-free survival compared with topotecan in patients with relapsed small cell lung cancer, supporting the...
Results from the phase 3...
09/27/2026
Oncology
FDA Approval
FDA Approves Belzutifan Plus Lenvatinib Following Immunotherapy in Advanced Clear Cell Renal Cell Carcinoma
09/24/2026
Emily Estrada
Based on results from the LITESPARK-011 trial, the FDA has approved belzutifan plus lenvatinib following PD-1 or PD-L1 inhibitor therapy for patients with advanced clear cell renal cell carcinoma, providing a new combination treatment option...
Based on results from the LITESPARK-011 trial, the FDA has approved belzutifan plus lenvatinib following PD-1 or PD-L1 inhibitor therapy for patients with advanced clear cell renal cell carcinoma, providing a new combination treatment option...
Based on results from the...
09/24/2026
Oncology
News
First-Line Zipalertinib Plus Chemotherapy Significantly Improves Progression-Free Survival in EGFR Exon 20-Mutated Non-Small Cell Lung Cancer
09/24/2026
Emily Estrada
Results from the phase 3 REZILIENT 3 trial showed that adding zipalertinib to platinum-pemetrexed chemotherapy significantly improved progression-free survival and response in patients with previously untreated EGFR exon 20 insertion-mutated...
Results from the phase 3 REZILIENT 3 trial showed that adding zipalertinib to platinum-pemetrexed chemotherapy significantly improved progression-free survival and response in patients with previously untreated EGFR exon 20 insertion-mutated...
Results from the phase 3...
09/24/2026
Oncology
News
Amivantamab Plus Chemotherapy Extends Median OS in Final PAPILLON Analysis of EGFR Exon 20-Mutant Non-Small Cell Lung Cancer
09/24/2026
Emily Estrada
Final results from the phase 3 PAPILLON trial showed numerically prolonged overall survival with first-line amivantamab plus chemotherapy in patients with EGFR exon 20 insertion-mutated non-small cell lung cancer, despite substantial...
Final results from the phase 3 PAPILLON trial showed numerically prolonged overall survival with first-line amivantamab plus chemotherapy in patients with EGFR exon 20 insertion-mutated non-small cell lung cancer, despite substantial...
Final results from the phase 3...
09/24/2026
Oncology
News
Acalabrutinib Plus Bendamustine and Rituximab Extends PFS and Delays Subsequent Therapy in Treatment-Naïve Patients With Mantle Cell Lymphoma
09/24/2026
Emily Estrada
Updated results from the phase 3 ECHO trial demonstrated that adding acalabrutinib to bendamustine and rituximab prolonged progression-free survival and delayed subsequent treatment in older patients with treatment-naïve mantle cell lymphoma,...
Updated results from the phase 3 ECHO trial demonstrated that adding acalabrutinib to bendamustine and rituximab prolonged progression-free survival and delayed subsequent treatment in older patients with treatment-naïve mantle cell lymphoma,...
Updated results from the phase 3...
09/24/2026
Oncology
News
Zidesamtinib Shows Durable Systemic and Intracranial Activity in Patients With TKI-Naïve ROS1-Positive Non-Small Cell Lung Cancer
09/24/2026
Emily Estrada
Results from the ARROS-1 trial demonstrated that zidesamtinib produced high and durable systemic and intracranial response in TKI-naïve patients with advanced ROS1-positive non-small cell lung cancer, supporting continued investigation of the...
Results from the ARROS-1 trial demonstrated that zidesamtinib produced high and durable systemic and intracranial response in TKI-naïve patients with advanced ROS1-positive non-small cell lung cancer, supporting continued investigation of the...
Results from the ARROS-1 trial...
09/24/2026
Oncology
FDA Alerts
FDA Advisory Committee Backs Galleri Multi-Cancer Early Detection Test for Adults Aged 50 Years and Older
09/24/2026
Stephanie Holland
An FDA advisory committee voted in favor of GRAIL’s Galleri multi-cancer early detection test for adults aged 50 years and older, supporting its safety, effectiveness, and overall benefit-risk profile as the agency continues review of its...
An FDA advisory committee voted in favor of GRAIL’s Galleri multi-cancer early detection test for adults aged 50 years and older, supporting its safety, effectiveness, and overall benefit-risk profile as the agency continues review of its...
An FDA advisory committee voted...
09/24/2026
Oncology
FDA Approval
FDA Approves Lirafugratinib for Previously Treated FGFR2-Altered Cholangiocarcinoma
09/23/2026
Emily Estrada
Based on results from the REFOCUS trial, the FDA has approved lirafugratinib for previously treated patients with unresectable or advanced FGFR2-altered cholangiocarcinoma, providing an additional targeted treatment option for patients with...
Based on results from the REFOCUS trial, the FDA has approved lirafugratinib for previously treated patients with unresectable or advanced FGFR2-altered cholangiocarcinoma, providing an additional targeted treatment option for patients with...
Based on results from the...
09/23/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use